Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)

Resubmission to FDA planned for early 2024 CRANFORD, N.J., Sept. 8, 2023 -- (Healthcare Sales & Marketing Network) -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has rec... Biopharmaceuticals, Oncology, FDA Citius Pharmaceuticals, LYMPHIR, denileukin diftitox, T-cell lymphoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news